fenofibrate + pravastatin

**UIC202006** is the Korea United Pharm trial identifier for **Pravafenix**, an oral fixed-dose lipid-modifying combination of fenofibrate 160 mg and pravastatin sodium 40 mg. It is used for mixed dyslipidemia in adults at high cardiovascular risk whose LDL cholesterol is adequately controlled with pravastatin but who retain elevated triglycerides and low HDL cholesterol. Fenofibrate is a prodrug whose active metabolite activates peroxisome proliferator-activated receptor alpha, increasing triglyceride clearance, while pravastatin inhibits 3-hydroxy-3-methylglutaryl-coenzyme A reductase to reduce hepatic cholesterol synthesis and LDL cholesterol. The exact UIC202006 code is documented in a Korea United Pharm Phase 1 pharmacokinetic study; Korean reporting identifies it as Yooyoung Pharmaceutical's Pravafenix comparator product. ([clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07691268))

Brand names

Pravafenix프라바페닉스캡슐

Other names

fenofibrate/pravastatinpravastatin + fenofibratepravastatin sodium + fenofibratepravastatin/fenofibratepravastatin sodium/fenofibrate